Fe3O4/MnO hybrid nanocrystals as a dual contrast agent for both T1- and T2-weighted liver MRI

Biomaterials

Volumn 34, Issue 8, 2013, Pages 2069-2076

  Im, Geun Ho ^a   Kim, Soo Min ^b   Lee, Dong Gyu ^b   Lee, Won Jae ^c   Lee, Jung Hee ^a   Lee, In Su ^b  

^a Samsung Medical Center   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Contrast agent; Dual contrast agent; Liver; MRI (magnetic resonance imaging); Nanoparticle

Indexed keywords

CONSPICUITY; CONTRAST AGENT; CONTRAST EFFECTS; CONTRAST ENHANCEMENT; CONTRAST-ENHANCED MR; HEPATOCELLULAR CARCINOMA; IN-VITRO; IN-VIVO; LIVER MRI; MAGNETIC RESONANCE CONTRAST AGENTS; MR CONTRAST AGENTS; MR IMAGING; MRI (MAGNETIC RESONANCE IMAGING); ORTHOTOPIC;

LIVER; MAGNETIC RESONANCE IMAGING; MANGANESE; MANGANESE OXIDE; NANOPARTICLES;

NANOCRYSTALS;

MAGNETITE NANOPARTICLE; MANGANESE OXIDE; NANOCRYSTAL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BRAIN; CONTRAST MEDIA; FERRIC COMPOUNDS; HUMANS; LIVER; LIVER NEOPLASMS; MAGNETIC PHENOMENA; MAGNETIC RESONANCE IMAGING; MANGANESE COMPOUNDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OXIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871522844     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.11.054     Document Type: Article

References (60)

1. Terreno E., Castelli D.D., Viale A., Aime S. Challenges for molecular magnetic resonance imaging. Chem Rev 2010, 110:3019-3042.
2. Louie A. Multimodality imaging probes: design and challenges. Chem Rev 2010, 110:3146-3195.
3. Hao R., Xing R., Xu Z., Hou Y., Gao S., Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater 2010, 22:2729-2742.
4. Laurent S., Forge D., Port M., Roch A., Robic C., Elst L.V., et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108:2064-2110.
5. Schladt T.D., Schneider K., Schild H., Tremel W. Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 2011, 40:6315-6343.
6. 3-rich tumor cells. J Am Chem Soc 2008, 130:7542-7543.
7. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
8. de Vries I.J., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005, 23:1407-1413.
9. Lee J.H., Huh Y.M., Jun Y., Seo J., Jang J., Song H.T., et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007, 13:95-99.
10. Castelli D.D., Gianolio E., Crich S.G., Terreno E., Aime S. Metal containing nanosized systems for MR-molecular imaging applications. Coord Chem Rev 2008, 252:2424-2443.
11. DrahoŠ B., LukeŠ I., Tóth é Manganese(II) complexes as potential contrast agents for MRI. Eur J Inorg Chem 2012, 12:1975-1986.
12. Kueny-Stotz M., Garofalo A., Felder-Flesch D. Manganese-enhanced MRI contrast agents: from small chelates to nanosized hybrids. Eur J Inorg Chem 2012, 12:1987-2005.
13. Pan D., Schmieder A.H., Wickline S.A., Lanza G.M. Manganese-based MRI contrast agents: past, present, and future. Tetrahedron 2011, 67:8431-8444.
14. Yoon Y., Lee B.I., Lee K.S., Im G.H., Byeon S.H., Lee J.H., et al. Surface modification of exfoliated layered gadolinium hydroxide for the development of multimodal contrast agents for MRI and fluorescence imaging. Adv Funct Mater 2009, 19:3375-3380.
15. Hifumi H., Yamaoka S., Tanimoto A., Citterio D., Suzuki K. Gadolinium-based hybrid nanoparticles as a positive MR contrast agent. J Am Chem Soc 2006, 128:15090-15091.
16. 4 nanocrystals as potential optical/magnetic multimodal bioprobes. J Am Chem Soc 2012, 134:1323-1330.
17. Taylor K.M.L., Kim J.S., Rieter W.J., An H., Lin W., Lin W. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J Am Chem Soc 2008, 130:2154-2155.
18. Bridot J.L., Faure A.C., Laurent S., Rivière C., Billotey C., Hiba B., et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 2007, 129:5076-5084.
19. Manus L.M., Mastarone D.J., Waters E.A., Zhang X.Q., Schultz-Sikma E.A., MacRenaris K.W., et al. Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett 2010, 10:484-489.
20. Song Y., Xu X., MacRenaris K.W., Zhang X.Q., Mirkin C.A., Meade T.J. Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging. Angew Chem Int Ed 2009, 48:9143-9147.
21. Pan D., Caruthers S.D., Hu G., Senpan A., Scott M.J., Gaffney P.J., et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 2008, 130:9186-9187.
22. Taylor K.M.L., Rieter W.J., Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J Am Chem Soc 2008, 130:14358-14359.
23. Tu C., Ma X., Pantazis P., Kauzlarich S.M., Louie A.Y. Paramagnetic, silicon quantum dots for magnetic resonance and two-photon imaging of macrophages. J Am Chem Soc 2010, 132:2016-2023.
24. 1 MRI contrast agents. J Mater Chem 2009, 19:6267-6273.
25. 1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed 2007, 46:5397-5401.
26. Pan D., Senpan A., Caruthers S.D., Williams T.A., Scott M.J., Gaffney P.J., et al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun 2009, 22:3234-3236.
27. 2 core/shell nanocomposites. ACS Nano 2011, 5:4177-4187.
28. Schladt T.D., Shukoor M.I., Schneider K., Tahir M.N., Natalio F., Ament I., et al. AuMnO nanoflowers: hybrid nanocomposites for selective dual functionalization and imaging. Angew Chem Int Ed 2010, 49:3976-3980.
29. Shin J., Anisur R.M., Ko M.K., Im G.H., Lee J.H., Lee I.S. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Ed 2009, 48:321-324.
30. Ha T.L., Kim H.J., Shin J., Im G.H., Lee J.W., Heo H., et al. Development of target-specific multimodality imaging agent by using hollow manganese oxide nanoparticles as a platform. Chem Commun 2011, 47:9176-9178.
31. 1 contrast agents of different nanostructured morphologies. Biomaterials 2010, 31:4073-4078.
32. 1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J Am Chem Soc 2011, 133:2955-2961.
33. Yang H., Zhuang Y., Hu H., Du X., Zhang C., Shi X., et al. Silica-coated manganese oxide nanoparticles as a platform for targeted magnetic resonance and fluorescence imaging of cancer cells. Adv Funct Mater 2010, 20:1733-1741.
34. Bennewitz M.F., Lobo T.L., Nkansah M.K., Ulas G., Brudvig G.W., Shapiro E.M. Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI. ACS Nano 2011, 5:3438-3446.
35. Lee Y.C., Chen D.Y., Dodd S.J., Bouraoud N., Koretsky A.P., Krishnan K.M. The use of silica coated MnO nanoparticles to control MRI relaxivity in response to specific physiological changes. Biomaterials 2012, 33:3560-3567.
36. 1 contrast agents for magnetic resonance imaging. Angew Chem Int Ed 2011, 50:10589-10593.
37. 4/MnO hybrid nanocrystals: selective, magnetically recyclable catalyst systems. Chem Mater 2012, 24:682-687.
38. Schladt T.D., Graf T., Köhler O., Bauer H., Dietzsch M., Mertins J., et al. Synthesis and magnetic properties of FePtMnO nanoheteroparticles. Chem Mater 2012, 24:525-535.
39. Choi J., Lee J.H., Shin T.H., Song H.T., Kim E.Y., Cheon J. Self-confirming " AND" logic nanoparticles for fault-free MRI. J Am Chem Soc 2010, 132:11015-11017.
40. Santra S., Jativa S.D., Kaittanis C., Normand G., Grimm J., Perez J.M. Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent. ACS Nano 2012, 6:7281-7294.
41. Onuki Y., Jacobs I., Artemov D., Kato Y. Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. Biomaterials 2010, 31:7132-7138.
42. * effect of iron particles. Magn Reson Med 2009, 61:1059-1065.
43. Morana G., Salviato E., Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007, 7:S24-S27.
44. Ward J. Use of contrast agents for liver MRI. Radiography 2007, 13:e54-e72.
45. Kim M.J., Kim J.H., Lim J.S., Oh Y.T., Chung J.J., Choi J.S., et al. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004, 20:612-621.
46. Kim S.K., Kim S.H., Lee W.J., Kim H., Seo J.W., Choi D., et al. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. Am J Roentgenol 2002, 179:741-750.
47. Kim H.J., Kim K.W., Byun J.H., Won H.J., Shin Y.M., Kim P.N., et al. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. Am J Roentgenol 2006, 186:1059-1066.
48. Weissleder R., Saini S., Stark D.D., Wittenberg J., Ferrucci J.T. Dual-contrast MR imaging of liver cancer in rats. Am J Roentgenol 1988, 150:561-566.
49. Ward J., Guthrie J.A., Scott D.J., Atchley J., Wilson D., Davies M.H., et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000, 216:154-162.
50. Martin D.R., Semelka R.C., Chung J.J., Balci N.C., Wilber K. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations. Magn Reson Imaging 2000, 18:955-963.
51. Dubertret B., Skourides P., Norris D.J., Noireaux V., Brivanlou A.H., Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002, 298:1759-1762.
52. Shtykova E.V., Huang X., Remmes N., Baxter D., Stein B., Dragnea B., et al. Structure and properties of iron oxide nanoparticles encapsulated by phospholipids with poly(ethylene glycol) tails. J Phys Chem C 2007, 111:18078-18086.
53. Tromsdorf U.I., Bigall N.C., Kaul M.G., Bruns O.T., Nikolic M.S., Mollwitz B., et al. Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett 2007, 7:2422-2427.
54. 2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med 1995, 34:227-233.
55. Huang J., Bu L., Xie J., Chen K., Cheng Z., Li X., et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 2010, 4:7151-7160.
56. Duan H., Kuang M., Wang X., Wang Y.A., Mao H., Nie S. Reexamining the effects of particle size and surface chemistry on the magnetic properties of iron oxide nanocrystals: new insights into spin disorder and proton relaxivity. J Phys Chem C 2008, 112:8127-8131.
57. 2 relaxivity. J Magn Reson Imaging 2007, 26:1634-1641.
58. 1 contrast. Magn Reson Med 2005, 53:640-648.
59. Silva A.C., Lee J.H., Aoki I., Koretsky A.P. Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. NMR Biomed 2004, 17:532-543.
60. Shapiro E.M., Koretsky A.P. Convertible manganese contrast for molecular and cellular MRI. Magn Reson Med 2008, 60:265-269.